Causes and consequences of increased sympathetic activity in renal disease

被引:150
作者
Joles, JA [1 ]
Koomans, HA [1 ]
机构
[1] Univ Med Ctr, Dept Hypertens & Nephrol, NL-3508 GA Utrecht, Netherlands
关键词
renal disease; antihypertensive agents; hypertension; diabetic nephropathy; sympathetic nervous system;
D O I
10.1161/01.HYP.0000121881.77212.b1
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Much evidence indicates increased sympathetic nervous activity (SNA) in renal disease. Renal ischemia is probably a primary event leading to increased SNA. Increased SNA often occurs in association with hypertension. However, the deleterious effect of increased SNA on the diseased kidney is not only caused by hypertension. Another characteristic of renal disease is unbalanced nitric oxide (NO) and angiotensin (Ang) activity. Increased SNA in renal disease may be sustained because a state of NO-Ang II unbalance is also present in the hypothalamus. Very few studies have directly compared the efficacy of adrenergic blockade with other renoprotective measures. Third-generation beta-blockers seem to have more protective effects than traditional beta-blockers, possibly via stimulation of NO release. Although it has been extensively documented that muscle SNA is increased in chronic renal failure, data on renal SNA and cardiac SNA are not available for these patients before end-stage renal disease. It is also unknown whether additional treatment with third-generation beta-blockers can delay the progression of renal injury and prevent cardiac injury in chronic renal failure more efficiently than conventional treatment with angiotensin-converting enzyme inhibitors only.
引用
收藏
页码:699 / 706
页数:8
相关论文
共 100 条
[51]   Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model [J].
Lan, HY ;
Mu, W ;
Tomita, N ;
Huang, XR ;
Li, JH ;
Zhu, HJ ;
Morishita, R ;
Johnson, RJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (06) :1535-1548
[52]   Antihypertensive therapy in chronic renal disease: a place for sympathicolytic agents? [J].
Laverman, GD ;
Remuzzi, G .
JOURNAL OF HYPERTENSION, 2003, 21 (09) :1625-1626
[53]   Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure [J].
Ligtenberg, G ;
Blankestijn, PJ ;
Oey, PL ;
Klein, IHH ;
Dijkhorst-Oei, LT ;
Boomsma, F ;
Wieneke, GH ;
van Huffelen, AC ;
Koomans, HA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) :1321-1328
[54]   Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency [J].
Mackie, FE ;
Campbell, DJ ;
Meyer, TW .
KIDNEY INTERNATIONAL, 2001, 59 (04) :1458-1465
[55]   Effect of blockade of endogenous angiotensin II on baroreflex function in conscious diabetic rats [J].
Maliszewska-Scislo, M ;
Scislo, TJ ;
Rossi, NF .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 284 (05) :H1601-H1611
[56]   Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community [J].
Manjunath, G ;
Tighiouart, H ;
Ibrahim, H ;
MacLeod, B ;
Salem, DN ;
Griffith, JL ;
Coresh, J ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (01) :47-55
[57]   Neural regulation of blood pressure by leptin and the related peptides [J].
Matsumura, K ;
Tsuchihashi, T ;
Fujii, K ;
Iida, M .
REGULATORY PEPTIDES, 2003, 114 (2-3) :79-86
[58]   HYPERTENSION INDUCED BY NITRIC-OXIDE SYNTHESIS INHIBITION IS RENAL NERVE DEPENDENT [J].
MATSUOKA, H ;
NISHIDA, H ;
NOMURA, G ;
VANVLIET, BN ;
TOSHIMA, H .
HYPERTENSION, 1994, 23 (06) :971-975
[59]  
Matsuoka H, 1993, Diabetes Res, V23, P19
[60]   MUSCLE SYMPATHETIC-NERVE ACTIVITY IN RENOVASCULAR HYPERTENSION AND PRIMARY ALDOSTERONISM [J].
MIYAJIMA, E ;
YAMADA, Y ;
YOSHIDA, Y ;
MATSUKAWA, T ;
SHIONOIRI, H ;
TOCHIKUBO, O ;
ISHII, M .
HYPERTENSION, 1991, 17 (06) :1057-1062